14-3-3ε-dependent deubiquitination and translocation of NLRP3 activates the inflammasome during sepsis.
Summary
This mechanistic study identifies 14-3-3ε as a positive regulator of NLRP3 inflammasome activation via K63 deubiquitination and MAM translocation, with elevated plasma levels correlating with sepsis severity. Genetic deletion in macrophages or pharmacologic inhibition with BV02 improved survival and organ injury in septic mice, nominating 14-3-3ε as a therapeutic target.
Key Findings
- 14-3-3ε binds NLRP3 and promotes K63 deubiquitination and translocation to MAMs for full inflammasome activation.
- Plasma 14-3-3ε is elevated in sepsis patients and correlates with disease severity.
- Macrophage-specific 14-3-3ε knockout or pharmacologic inhibition (BV02) improves survival and reduces organ injury in septic mice.
Clinical Implications
If validated clinically, selective inhibition of 14-3-3ε–NLRP3 interactions could attenuate hyperinflammation in sepsis without broad immunosuppression.
Why It Matters
It reveals a druggable node upstream of NLRP3 with in vivo survival benefit, bridging molecular mechanism, human correlation, and therapeutic modulation.
Limitations
- Human cohort size and sampling details are not specified; patient findings are correlative.
- BV02 specificity and safety in humans remain untested; mouse sepsis models may not fully recapitulate human disease.
Future Directions
Develop selective inhibitors disrupting 14-3-3ε–NLRP3 interaction, and validate 14-3-3ε as a biomarker and target in multicenter human studies.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- V - Mechanistic laboratory study with animal models and limited human correlative data
- Study Design
- OTHER